Core Insights - Lavie Bio is a leader in the ag-biologicals industry with a strong pipeline of microbiome-based products [1] - ICL will acquire key assets from Lavie Bio, including its core team, BDD technology platform, microbial bank, and commercial products [1] - The transaction follows over two years of collaboration between ICL and Lavie Bio to develop bio-stimulant solutions for crops [2] - The integration aims to accelerate the development of innovative ag-biological products for global agriculture [3] Company Overview - Lavie Bio, a subsidiary of Evogene Ltd., focuses on enhancing food quality and agricultural productivity through microbiome-based products [4] - The company utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's MicroBoost AI technology [4] - Evogene Ltd. aims to revolutionize life-science product development using advanced technologies to improve success rates and reduce costs [6] Strategic Implications - The acquisition is expected to significantly advance the global ag-biologicals field and foster impactful agricultural innovations [3] - Existing agreements between Lavie Bio and its partners will remain with Lavie Bio, potentially generating future revenue for its shareholders [1]